Medicine
Pertzye 60500 units/16000 units/57500 units delayed-release capsule
Pertzye 60500 units/16000 units/57500 units delayed-release capsule is a prescription medicine containing Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for oral use, marketed by Digestive Care, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store PERTZYE at room temperature 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease
- Brand
- Pertzye
- Strength
- 60500 units/16000 units/57500 units
- Dosage form
- Delayed-release capsule
- Route
- Oral
- Packs
- 100 capsules, 250 capsules
- Marketing authorisation holder
- Digestive Care
- Manufacturer
- Digestive Care
- Origin register
- US FDA, United States
- Storage
- Store PERTZYE at room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 40°C (59°F to 104°F) for up to 30 days. PERTZYE hard gelatin capsules should be stored in a dry place in the original container or equivalent airtight container. After opening, keep the container tightly closed between uses to protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 May 2012
- Identifiers
- RxCUI 1294122, 1294128, 1294481 +5DailyMed set ID 481eec00-9abf-11dd-b71c-0002a5d5c51bNDC 59767-016Application BLA022175
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 capsule, delayed release in 1 bottle | 59767-016-01 | Digestive Care | 17 May 2012 |
| 250 capsule, delayed release in 1 bottle | 59767-016-02 | Digestive Care | 17 May 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease
Clinical summary
Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease is a fixed-dose combination medicine indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. MedsAcross supplies Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Pancrelipase amylase, Pancrelipase lipase and Pancrelipase proteaseFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zenpep prescribing information (Aimmune Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Pertzye 60500 units/16000 units/57500 units delayed-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.